Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact
Login Book a demo
Delcath Systems logo — Delcath Systems, Inc. is an interventional oncology company...

Delcath Systems

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of metastatic liver cancer.

Founded 1987 United States New York, United States 86 employees Post-IPO Equity Total: $276.60M Biotechnology, Health Care +1

General Information

Company Name Delcath Systems
Founded Year 1987
Location United States New York, United States
Founders / Decision Makers
Team member Team member Team member
Employees 86
Industries Biotechnology, Health Care, Pharmaceutical
Funding Stage Post-IPO Equity
Social

BounceWatch is an independent company data service, not affiliated with Delcath Systems. To contact Delcath Systems, visit delcath.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Delcath Systems compare?

A PDF of Delcath Systems and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Delcath Systems soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Delcath Systems

Delcath Systems, Inc. is an interventional oncology company with a focus on treating metastatic liver cancer. The company, listed on NASDAQ under the ticker symbol DCTH, specializes in the treatment of primary and metastatic liver cancers. Its proprietary product, Melphalan Hydrochloride for Injection, utilized with the Delcath Hepatic Delivery System (Melphalan/HDS), is designed for high-dose chemotherapy administration to the liver while controlling systemic exposure. Delcath is currently in late-stage clinical development in the United States, while already conducting commercial activities in Europe. In Europe, its product is marketed as the Delcath Hepatic CHEMOSAT® Delivery System for Melphalan (CHEMOSAT), a CE Marked device. The commercial strategy for CHEMOSAT revolves around growing clinical adoption in major European markets and leveraging physician experience to support appeals for reimbursement. To date, over 250 CHEMOSAT treatments have been performed at over 20 leading European cancer centers. In 2016, Delcath launched the FOCUS Pivotal Study in Hepatic Dominant Ocular Melanoma and has ongoing investigations in orphan indications related to hepatocellular carcinoma and intrahepatic cholangiocarcinoma. The company believes Melphalan/HDS is uniquely positioned to treat the entire liver as a stand-alone or complementary therapy. Delcath Systems, Inc. was founded in 1987 and is headquartered in the United States. The most recent investment in the company totaled $7.00M and was in the form of a Post-IPO Equity investment on 15 March 2024.

Business keywords: Interventional Oncology, Metastatic Liver Cancer, Medical Device, High-dose Chemotherapy, Clinical Development, Melphalan/HDS, CE Marked Device, European Market, FOCUS Pivotal Study, Hepatic Dominant Ocular Melanoma, Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, Liver Directed Therapy, Drug Delivery, Specialty Pharmaceutical

Funding Rounds & Investors (13)

View All
Funding Stage Amount Investors Lead Investors Date
Post IPO Equity $7.00M -
15 Mar 2024
Post IPO Equity $35.00M -
01 Sep 2023
Post IPO Equity $85.00M 5
Vivo Capital Logos Capital
Vivo Capital, Logos Capital +3
27 Mar 2023
Post IPO Equity $6.20M -
08 Dec 2022
Post IPO Equity $5.00M -
18 Jul 2022
Post IPO Debt $20.00M 1
Avenue Capital
Avenue Capital
09 Aug 2021
Post IPO Equity $22.20M -
11 Dec 2020
Post IPO Equity $20.00M -
23 Jul 2019
Post IPO Equity $5.00M -
12 Feb 2018
Post IPO Equity $2.00M -
06 Jul 2017

View All 13 Funding Rounds

Delcath Systems Alternatives & Competitors

View All Alternatives
Delcath Systems vs
Theromics Inc.
Theromics Inc. United States

Next-generation thermal accelerant technology for enhanced ablation and precision intratumoral drug...

Grant
11 employees
Biotechnology, Health Care
Compare Delcath Systems vs Theromics Inc.
Delcath Systems vs
Techsol Life Sciences
Techsol Life Sciences United States

Navigate To Excellence

322 employees
Health Care, Pharmaceutical
Compare Delcath Systems vs Techsol Life Sciences
Delcath Systems vs
Bioxis Pharmaceuticals
Bioxis Pharmaceuticals France

#BeyondInnovation #DermalFiller #CYTOSIAL #AestheticMedicine

Venture round
28 employees
Biotechnology, Medical Devices
View all alternatives

FAQ About Delcath Systems

Delcath Systems, Inc. is an interventional oncology company focused on the treatment of metastatic liver cancer.
Delcath Systems was founded in 1987.
Delcath Systems is headquartered in New York, United States.
Delcath Systems operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Interventional Oncology, Metastatic Liver Cancer, Medical Device and High-dose Chemotherapy.
Delcath Systems has approximately 86 employees.
Delcath Systems has completed 13 funding rounds, raising a total of $276.60M. The latest funding stage is Post-IPO Equity.
Top alternatives and competitors to Delcath Systems include Theromics Inc., Techsol Life Sciences, Bioxis Pharmaceuticals, Portal Instruments, Apellis Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Delcath Systems and Theromics Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Delcath Systems, https://bouncewatch.com/company/delcath-systems, updated 30 December 2024. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Book a demo 30 minutes